Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

作者: Deborah L. Ackerman , Sander Greenland

DOI: 10.1097/00004714-200206000-00012

关键词:

摘要: Meta-analytic reviews of placebo-controlled studies for obsessive-compulsive disorder have found that clomipramine is more effective than drugs with selective actions on serotonin reuptake, whereas in most direct comparisons, clomipramine's superiority has been less obvious. The authors used metaregression to identify sources he-terogeneity trials clomipramine, fluvoxamine, sertraline, and paroxetine. They evaluated such patient characteristics as age, gender, age (OCD) onset, baseline severity OCD depression, study exclusion or inclusion criteria, length single-blind prerandomization period, trial, number subjects, publication year. We considerable heterogeneity across was associated, part, year, patients' OCD. apparent persisted after controlling these factors. also confirmed previous reports placebo response higher recent studies. Meta-analyses can help characterize responders nonresponders. urge investigators provide summaries characteristics, especially severity, at duration OCD, by response.

参考文章(40)
C. P. L. Freeman, M. R. Trimble, T. M. Stokes, J. J. Ashford, J. F. W. Deakin, Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. The Journal of Clinical Psychiatry. ,vol. 55, pp. 301- 305 ,(1994)
J Greist, M Jenike, W Goodman, S Rasmussen, G Chouinard, M Gaffney, P A Bick, E Hackett, K White, Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology Bulletin. ,vol. 26, pp. 279- 284 ,(1990)
Joseph A. Tangrea, Maria Elena Adrianza, William E. Helsel, Risk factors for the development of placebo adverse reactions in a multicenter clinical trial Annals of Epidemiology. ,vol. 4, pp. 327- 331 ,(1994) , 10.1016/1047-2797(94)90089-2
W. K. Goodman, M. J. Kozak, M. Liebowitz, K. L. White, Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology. ,vol. 11, pp. 21- 30 ,(1996) , 10.1097/00004850-199603000-00003
Lorrin M. Koran, Susan L. McElroy, Jonathan R.T. Davidson, Steven A. Rasmussen, Eric Hollander, Michael A. Jenike, Fluvoxamine Versus Clomipramine for Obsessive-Compulsive Disorder Journal of Clinical Psychopharmacology. ,vol. 16, pp. 121- 129 ,(1996) , 10.1097/00004714-199604000-00004
DEBORAH L. ACKERMAN, SANDER GREENLAND, ALEXANDER BYSTRITSKY, HAL MORGENSTERN, RICHARD J. KATZ, Predictors of treatment response in obsessive-compulsive disorder : multivariate analyses from a multicenter trial of clomipramine Journal of Clinical Psychopharmacology. ,vol. 14, pp. 247- 254 ,(1994) , 10.1097/00004714-199408000-00004
A. Milanfranchi, S. Ravagli, P. Lensi, D. Marazziti, G. B. Cassano, A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology. ,vol. 12, pp. 131- 136 ,(1997) , 10.1097/00004850-199705000-00002